secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2025-08-29T23:59:59+00:00
Accession:  0000939767-25-000115
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis appoints Dana Aftab as EVP R&D; Amy Peterson departs as CMO
--------------------------------------------------------------------

- Dana Aftab, Ph.D., promoted to EVP of R&D effective August 29, 2025; previously EVP Discovery & CSO.
- Amy C. Peterson, M.D., concluded service as EVP Product Development and CMO on same date.
- Dr. Peterson eligible for severance under Exelixis's Change in Control and Severance Benefit Plan.
- No other officer changes disclosed; Dr. Aftab's compensation terms unchanged from prior proxy filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976725000115/0000939767-25-000115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976725000115/exel-20250829.htm
  HTML page:      https://secwatch.observer/filing/0000939767-25-000115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer